Clinical Application of Adaptive Immune Therapy in MSS Colorectal Cancer Patients

Colorectal cancer (CRC) is one of the most common cancers worldwide. However, the treatment outcomes of immunotherapy in microsatellite-stable (MSS) CRC remain unsatisfactory. As the majority of CRC cases display a molecular MSS/mismatch repair-proficient (pMMR) profile, it is particularly meaningfu...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 12; p. 762341
Main Authors:	Wang, Danyang, Zhang, Hangyu, Xiang, Tao, Wang, Gang
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 13-10-2021
Subjects:	adaptive immune response Animals Cancer Vaccines - therapeutic use CAR-T colorectal cancer Colorectal Neoplasms - immunology Colorectal Neoplasms - therapy Cytokines - immunology Humans Immune Checkpoint Inhibitors - therapeutic use immune therapy Immunology Immunotherapy Microsatellite Instability Receptors, Immunologic - immunology vaccines immune therapy colorectal cancer adaptive immune response CAR-T vaccines
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Colorectal cancer (CRC) is one of the most common cancers worldwide. However, the treatment outcomes of immunotherapy in microsatellite-stable (MSS) CRC remain unsatisfactory. As the majority of CRC cases display a molecular MSS/mismatch repair-proficient (pMMR) profile, it is particularly meaningful to explore the clinical applications of adaptive immune therapy in MSS CRC patients. In this review, we summarized the therapeutic approaches of adoptive immune therapies, including cytokines, therapeutic cancer vaccines, adoptive T-cell therapy, and immune checkpoint inhibitors, in the treatment of MSS CRCs.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Edited by: Nurit Hollander, Tel Aviv University, Israel These authors have contributed equally to this work Reviewed by: Raheleh Roudi, University of Minnesota, United States; Xianda Zhao, University of Minnesota, United States This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2021.762341